Clomid vs Progesterone (Luteal Support): Which One Actually Helps You Get Pregnant?

Why This Comparison Is Trickier Than It Looks

Clomiphene and luteal-phase progesterone are both "fertility drugs," but placing them in a head-to-head bracket misses how they actually work. They act on different phases of the menstrual cycle, target different biological problems, and are measured by different outcomes.

The short answer: no randomized trial has ever directly compared clomiphene to luteal progesterone as competing treatments in the same population, because they address separate physiological bottlenecks. Clomiphene solves the problem of not ovulating. Progesterone solves the problem of a luteal phase that cannot sustain a pregnancy after ovulation has already happened.

Understanding this framework changes everything about how you read your own treatment plan. If your doctor prescribes both, that is not redundancy. It means your cycle had two problems that needed two solutions at two different timepoints.

What Clomiphene (Clomid) Actually Does in Your Body

Clomiphene is a selective estrogen-receptor modulator. It binds estrogen receptors in the hypothalamus, blocking the normal negative feedback signal that estrogen sends to slow down FSH production. Your pituitary responds by releasing a larger FSH pulse, which recruits one or more ovarian follicles and drives ovulation in women who were not ovulating on their own.

How It Is Prescribed

The standard starting dose is 50 mg orally for 5 days, beginning on cycle day 3, 4, or 5. If ovulation does not occur, the dose is stepped up to 100 mg and then 150 mg in subsequent cycles. ACOG recommends limiting clomiphene use to six ovulatory cycles because cumulative exposure beyond that has not been shown to improve cumulative live-birth rates and raises theoretical ovarian cancer concerns with longer use.

Ovulation and Pregnancy Rates

The landmark data come from the NEJM 2014 trial by Legro et al., which randomized 750 women with PCOS to clomiphene or letrozole. Clomiphene produced ovulation in approximately 73% of treated cycles, though the live-birth rate per woman over the trial period was 19.1% with clomiphene versus 27.5% with letrozole. That gap matters: ovulation rates do not equal live-birth rates, partly because clomiphene's anti-estrogenic effect on the endometrium may impair implantation even when it successfully induces ovulation.

Who Benefits Most from Clomiphene

• Women with anovulatory infertility, most commonly from PCOS
• Women with hypothalamic amenorrhea (selected cases)
• Women in their late twenties and thirties with confirmed ovulatory dysfunction and a partner with normal semen analysis
• Women using intrauterine insemination (IUI) who need controlled follicular recruitment

Clomiphene is less effective for women with diminished ovarian reserve, because the problem is not FSH signaling but follicle quantity. It is also less effective for women with tubal factor or male-factor infertility, where ovulation is not the limiting step.

Female-Specific Side Effects

Because clomiphene blocks estrogen receptors across multiple tissues, the side effects in women are distinct from those in men (who sometimes use it off-label). You may notice:

• Hot flashes and mood changes that mimic perimenopause symptoms (estrogen blockade is the direct cause)
• Cervical mucus thinning, which can paradoxically reduce sperm penetration even as ovulation improves
• Ovarian hyperstimulation syndrome (OHSS), though the risk is lower with clomiphene than with injectable gonadotropins
• Visual disturbances, which warrant immediate discontinuation
• Multiple gestation: twin rate is approximately 6-8% with clomiphene, compared to about 1% in spontaneous conception

What Luteal-Phase Progesterone Does in Your Body

After ovulation, the follicle that released your egg collapses into the corpus luteum, which produces progesterone for approximately 10-14 days. Progesterone transforms the uterine lining from the proliferative phase into the secretory phase, making it receptive to a fertilized embryo. If implantation occurs, hCG from the developing embryo signals the corpus luteum to keep producing progesterone until the placenta takes over at around 8-10 weeks.

When this progesterone signal is insufficient, abbreviated, or artificially disrupted, luteal-phase defect (LPD) occurs and implantation may fail or early pregnancy loss may follow.

When Luteal Support Is Prescribed

Luteal progesterone is standard of care in three clinical situations:

1. After IVF or frozen embryo transfer (FET), where the retrieval process or GnRH agonist/antagonist protocols suppress the corpus luteum
2. After IUI combined with ovulation induction, where the hormonal environment may produce an inadequate luteal phase
3. In women with documented recurrent pregnancy loss thought to be related to luteal insufficiency

The Cochrane systematic review by van der Linden et al. (2015) analyzed progesterone luteal support in fresh IVF cycles and found a statistically significant improvement in live-birth rates compared to placebo or no treatment. That review pooled data from multiple RCTs and is the evidence backbone for current IVF protocols worldwide.

Route of Delivery Matters

Vaginal micronized progesterone (200-400 mg nightly or twice daily, most commonly Prometrium, Endometrin, or Crinone gel) achieves high local uterine tissue concentrations through a "first-uterine-pass" effect, with relatively low serum levels. ASRM practice guidelines support vaginal administration as the primary route for luteal support in ART cycles because uterine tissue concentrations are higher than with equivalent intramuscular dosing.

Intramuscular progesterone in oil (typically 50 mg/day) produces higher serum levels and is used when vaginal absorption is unreliable or when a provider prefers measurable serum confirmation of adequacy.

Female-Specific Side Effects

• Bloating, breast tenderness, and fatigue are common, particularly in the two-week wait after embryo transfer
• Vaginal discharge and mild irritation with suppositories
• Drowsiness if oral micronized progesterone is used (it is extensively metabolized to allopregnanolone, a neurosteroid with sedating properties)
• Serum progesterone levels measured after vaginal administration are not reliable surrogates for uterine tissue levels, which sometimes leads to unnecessary dose changes based on blood draws

Head-to-Head Efficacy: What the Evidence Actually Shows

No published RCT has randomized women to clomiphene versus luteal progesterone as competing single-drug strategies for achieving live birth. That trial does not exist, and it would not make clinical sense to design one, because the drugs act at different cycle phases for women with different underlying problems.

What the evidence does show, from separate trial programs:

| Outcome | Clomiphene (Legro 2014, PCOS) | Luteal Progesterone (Cochrane 2015, IVF) | |---|---|---| | Ovulation rate per cycle | ~73% | Not applicable (ovulation has already occurred) | | Live-birth rate | 19.1% per woman over trial | Significantly higher vs placebo in IVF | | Population studied | Anovulatory PCOS | Women undergoing fresh IVF | | Phase of cycle | Follicular (days 3-7) | Luteal (post-retrieval or post-transfer) | | Direct comparison exists | No | No |

Why the Legro 2014 Live-Birth Rate Seems Low

The 19.1% live-birth rate for clomiphene in Legro 2014 is a cumulative rate across all enrolled women over the full trial, not a per-cycle rate. Women who did not ovulate or did not conceive contributed to the denominator. Per-ovulatory-cycle pregnancy rates with clomiphene in appropriately selected women are approximately 10-20%, which aligns with natural fecundability in fertile couples.

The Case for Using Both Together

In IUI cycles where clomiphene is used for ovulation induction, some clinicians add luteal progesterone because the clomiphene-stimulated cycle may produce a suboptimal corpus luteum. The data here are mixed. A 2014 meta-analysis published in Fertility and Sterility found that luteal progesterone supplementation in IUI cycles showed a trend toward improved pregnancy rates, but the benefit was not statistically significant across all subgroups. The strongest signal appeared in women who were also using gonadotropins rather than clomiphene alone.

ASRM does not currently mandate luteal support for all clomiphene-IUI cycles, but many clinicians prescribe it anyway, particularly after repeated failed cycles or in women with suspected LPD.

Life-Stage Differences: How Your Hormonal Status Changes the Calculation

Reproductive Years, Trying to Conceive (Ages 18-35)

This is the primary population for both drugs. Clomiphene is almost always the first-line ovulation induction agent in anovulatory women with normal ovarian reserve. The ACOG practice bulletin on infertility places clomiphene as first-line before gonadotropins in this group, citing the lower OHSS risk and oral dosing convenience.

Luteal progesterone in this age group is reserved for IVF cycles, documented LPD, or recurrent loss. It is not routinely prescribed for natural cycles in women under 35 with no prior losses.

Ages 35-40, Diminished Ovarian Reserve

Clomiphene's effectiveness drops as ovarian reserve falls, because the problem shifts from signaling to supply. AMH below 1.0 ng/mL or antral follicle count below 6 predicts poor response to clomiphene. In this group, gonadotropins or IVF with luteal progesterone support becomes the preferred path faster than in younger women.

PCOS Across Reproductive Years

PCOS affects approximately 8-13% of women of reproductive age and is the most common indication for clomiphene. Women with PCOS who do ovulate with clomiphene may still benefit from luteal support, because the hormonal milieu in PCOS (elevated LH, insulin resistance, androgen excess) can disrupt corpus luteum function even after successful ovulation.

The Legro 2014 NEJM trial was conducted entirely in women with PCOS. The finding that letrozole outperformed clomiphene in live-birth rates has shifted many practices toward letrozole as first-line in PCOS, though ASRM and ACOG both acknowledge clomiphene as an acceptable first-line option when letrozole is unavailable or not tolerated.

Perimenopause and Late Reproductive Years (Ages 40-45)

Anovulatory cycles become more frequent in perimenopause, but fertility declines steeply. Clomiphene can induce ovulation in perimenopausal women, but the egg quality and ovarian reserve concerns mean the drug is rarely used as a standalone fertility treatment beyond age 42 without a full workup. Some clinicians use low-dose clomiphene off-label in this age group for cycle regularity, but this is not FDA-approved and the evidence is thin.

Luteal progesterone is sometimes used in perimenopause for cycle management and endometrial protection (oral micronized progesterone 200 mg for 14 days per month), but this is a different indication from fertility-related luteal support and uses different dosing.

Pregnancy and Lactation Safety: What You Must Know

Clomiphene in Pregnancy and Lactation

Clomiphene is contraindicated once pregnancy is confirmed. The FDA originally assigned it Pregnancy Category X based on animal teratogenicity data and case reports of congenital anomalies in humans. FDA label data state that clomiphene should be discontinued immediately if pregnancy is confirmed during a treatment cycle.

The human teratogenicity data are conflicting. Large registry studies have not confirmed a strong teratogenic signal at standard doses, but the theoretical risk from estrogen-receptor blockade during organogenesis justifies the contraindication. You should use a reliable method of tracking ovulation (LH testing or ultrasound monitoring) so that you can confirm ovulation timing and avoid ongoing exposure into a luteal phase where you may already be pregnant.

Clomiphene transfer into breast milk has not been adequately studied. Given its estrogen-receptor modulating properties, it is generally avoided during lactation.

Contraception note: Women taking clomiphene who do not want to conceive need effective contraception, because ovulation will be induced. This sounds counterintuitive given the drug's fertility indication, but it applies in off-label uses such as hypothalamic dysfunction treatment.

Progesterone in Pregnancy and Lactation

Micronized progesterone has a well-established safety record in early pregnancy. It is FDA-approved for luteal supplementation in ART and is used by most IVF programs from the day of egg retrieval through 10-12 weeks of gestation. A large observational study published in AJOG found no increased risk of congenital anomalies with vaginal micronized progesterone compared to intramuscular progesterone in IVF pregnancies.

Progesterone is a naturally occurring hormone that the corpus luteum and then the placenta produce throughout pregnancy. Exogenous supplementation in the first trimester mirrors physiological levels and is not considered teratogenic.

Regarding lactation: micronized progesterone does transfer into breast milk in small amounts, but endogenous progesterone is already present in breast milk throughout lactation. At clinical doses for luteal support, the transfer is not considered clinically significant. However, starting progesterone supplementation during active lactation in a non-ART context should be discussed with your provider, because any progestogen can theoretically reduce milk supply in some women.

Who This Approach Is Right For (and Who It Is Not)

Clomiphene Is Likely Right for You If:

• You have confirmed anovulation (PCOS, hypothalamic dysfunction, irregular cycles)
• Your ovarian reserve is within normal range for your age (AMH above 1.0 ng/mL, AFC above 6)
• You have patent fallopian tubes on HSG
• Your partner's semen analysis is normal or mildly abnormal
• You have not responded to lifestyle modification and metformin alone (in PCOS)
• You are in your reproductive years, generally ages 18-40

Clomiphene Is Not the Right First Step If:

• You ovulate regularly and the fertility problem lies elsewhere (tubal, uterine, severe male factor)
• Your ovarian reserve is low for your age
• You have already completed six cycles without conception (ACOG recommends moving to the next treatment tier)
• You have had clomiphene-resistant PCOS (no ovulation at 150 mg)
• You are already pregnant

Luteal Progesterone Is Right for You If:

• You are undergoing IVF or frozen embryo transfer (essentially universal indication)
• You are doing IUI with gonadotropins and have had multiple failed cycles
• You have documented luteal-phase defect on endometrial biopsy or serial progesterone draws
• You have recurrent early pregnancy loss with suspected luteal insufficiency
• Your IVF cycle used a GnRH agonist or antagonist protocol that suppresses corpus luteum function

Luteal Progesterone Is Not Clearly Indicated If:

• You are conceiving naturally with confirmed ovulatory cycles and no history of loss
• You are under 35 with a single prior loss (recurrent loss is generally defined as two or more)
• You are seeking it as a general "boost" without documented luteal insufficiency in a natural cycle

A Note on Evidence Gaps for Women

The clinical trial field for both drugs has an underrepresentation problem specific to certain female subgroups. The Legro 2014 NEJM trial enrolled only women with PCOS, so the clomiphene ovulation and live-birth data extrapolated to non-PCOS anovulatory populations come from older, smaller studies. The Cochrane 2015 luteal support review covers IVF populations, which skew toward women with infertility diagnoses of longer duration and do not represent typical ovulatory women adding progesterone after natural conception.

Data on clomiphene in women over 40, women with premature ovarian insufficiency, and women who are postpartum are sparse. Luteal-support data for IUI cycles in women without IVF remain limited to smaller RCTs with varying designs, which is why ASRM has not issued a firm universal recommendation for progesterone in all IUI cycles.

When your provider says "the evidence supports" either drug for your specific situation, ask whether the trial populations looked like you: your age, your PCOS status, your ovarian reserve, your ART context.

Practical Monitoring and What to Watch

During Clomiphene Cycles

Track ovulation with urine LH tests starting on cycle day 10 if you begin clomiphene on day 5. Many practices perform a midcycle ultrasound to confirm follicle growth and prevent hyperstimulation. A serum progesterone drawn 7 days after LH surge (mid-luteal) above 3 ng/mL confirms ovulation occurred; a level above 10 ng/mL suggests adequate corpus luteum function.

During Luteal Progesterone Supplementation

Serum progesterone monitoring after vaginal administration is unreliable as a dose-adjustment tool. A 2021 analysis in Fertility and Sterility found that uterine tissue progesterone concentrations with vaginal micronized progesterone 200 mg twice daily were adequate for implantation support even when serum levels appeared low (often 10-20 ng/mL, versus the 20-40 ng/mL expected with IM dosing). Do not let a low serum number alone drive a switch to IM progesterone without a full clinical conversation.

Progesterone supplementation is typically tapered and stopped between 8 and 12 weeks of gestation once placental progesterone production is confirmed to be adequate.